Cargando…

The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke

Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xing-Hua, Yin, Feng-Ting, Zhou, Xiao-Hang, Zhang, Ai-Hua, Sun, Hui, Yan, Guang-Li, Wang, Xi-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148018/
https://www.ncbi.nlm.nih.gov/pubmed/35630576
http://dx.doi.org/10.3390/molecules27103099
_version_ 1784716949572288512
author Li, Xing-Hua
Yin, Feng-Ting
Zhou, Xiao-Hang
Zhang, Ai-Hua
Sun, Hui
Yan, Guang-Li
Wang, Xi-Jun
author_facet Li, Xing-Hua
Yin, Feng-Ting
Zhou, Xiao-Hang
Zhang, Ai-Hua
Sun, Hui
Yan, Guang-Li
Wang, Xi-Jun
author_sort Li, Xing-Hua
collection PubMed
description Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage, r-tPA is currently used in less than 5% of stroke patients. Natural compounds have been widely used in the treatment of IS in China and have a wide range of therapeutic effects on IS by regulating multiple targets and signaling pathways. The keywords “ischemia stroke, traditional Chinese Medicine, Chinese herbal medicine, natural compounds” were used to search the relevant literature in PubMed and other databases over the past five years. The results showed that JAK/STAT, NF-κB, MAPK, Notch, Nrf2, and PI3K/Akt are the key pathways, and SIRT1, MMP9, TLR4, HIF-α are the key targets for the natural compounds from traditional Chinese medicine in treating IS. This study aims to update and summarize the signaling pathways and targets of natural compounds in the treatment of IS, and provide a base of information for the future development of effective treatments for IS.
format Online
Article
Text
id pubmed-9148018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91480182022-05-29 The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke Li, Xing-Hua Yin, Feng-Ting Zhou, Xiao-Hang Zhang, Ai-Hua Sun, Hui Yan, Guang-Li Wang, Xi-Jun Molecules Review Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage, r-tPA is currently used in less than 5% of stroke patients. Natural compounds have been widely used in the treatment of IS in China and have a wide range of therapeutic effects on IS by regulating multiple targets and signaling pathways. The keywords “ischemia stroke, traditional Chinese Medicine, Chinese herbal medicine, natural compounds” were used to search the relevant literature in PubMed and other databases over the past five years. The results showed that JAK/STAT, NF-κB, MAPK, Notch, Nrf2, and PI3K/Akt are the key pathways, and SIRT1, MMP9, TLR4, HIF-α are the key targets for the natural compounds from traditional Chinese medicine in treating IS. This study aims to update and summarize the signaling pathways and targets of natural compounds in the treatment of IS, and provide a base of information for the future development of effective treatments for IS. MDPI 2022-05-12 /pmc/articles/PMC9148018/ /pubmed/35630576 http://dx.doi.org/10.3390/molecules27103099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Li, Xing-Hua
Yin, Feng-Ting
Zhou, Xiao-Hang
Zhang, Ai-Hua
Sun, Hui
Yan, Guang-Li
Wang, Xi-Jun
The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title_full The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title_fullStr The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title_full_unstemmed The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title_short The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
title_sort signaling pathways and targets of natural compounds from traditional chinese medicine in treating ischemic stroke
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148018/
https://www.ncbi.nlm.nih.gov/pubmed/35630576
http://dx.doi.org/10.3390/molecules27103099
work_keys_str_mv AT lixinghua thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT yinfengting thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT zhouxiaohang thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT zhangaihua thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT sunhui thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT yanguangli thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT wangxijun thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT lixinghua signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT yinfengting signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT zhouxiaohang signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT zhangaihua signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT sunhui signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT yanguangli signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke
AT wangxijun signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke